Quick Answer
Werewolf Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $57.05 million for the year ending 2025.
- Werewolf Therapeutics, Inc. showed a decrease of -48.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Werewolf Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $84.60 million | Q2 2021: $183.23 million | Q3 2021: $170.44 million | Q4 2021: $157.53 million | Q1 2022: $143.71 million | Q2 2022: $145.71 million | Q3 2022: $140.45 million | Q1 2023: $147.87 million | Q2 2023: $137.45 million | Q3 2023: $130.06 million | Q1 2024: $139.19 million | Q2 2024: $135.30 million | Q3 2024: $122.83 million | Q1 2025: $92.04 million | Q2 2025: $77.60 million | Q3 2025: $65.71 million.
- Over the full 6 years of available data (2020 to 2025), Werewolf Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 38.4%.
- Historical annual values: Fiscal year 2025: $57.05 million | Fiscal year 2024: $111.00 million | Fiscal year 2023: $134.34 million | Fiscal year 2022: $129.32 million | Fiscal year 2021: $157.53 million | Fiscal year 2020: $92.57 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: